Predictors of Adverse Events after Onabotulinumtoxina Treatment for Patients with Overactive Bladder Syndrome

Trial Profile

Predictors of Adverse Events after Onabotulinumtoxina Treatment for Patients with Overactive Bladder Syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Nov 2015 New trial record
    • 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top